This week, we’re sharing the most recent top stories in psychiatry news. A new study finds the percentage of respondents whose mental health wellbeing posed clinical risk in 2019 vs 2020, rose from 14% to 26% in correlation to covid-19 pandemic.
Additionally, a new ADHD medication, Azstarys receives FDA approval, and new results of a small, randomized trial show those who received ezogabine (Potiga) experienced a significant reduction in key measures of depression and anhedonia vs placebo.
Azstarys, a Once-Daily Treatment for ADHD, Gets FDA Approval Bloomberg, March 3, 2021
The Food and Drug Administration (FDA) has approved Azstarys™ (serdexmethylphenidate and dexmethylphenidate) capsules for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older.
Novel Alzheimer’s drug slows cognitive decline in phase 2 trial MDedge, March 16, 2021
Results from a phase 2 placebo-controlled trial of the investigational antiamyloid drug donanemab show that the novel agent met the primary outcome of slowing cognitive decline in patients with early symptomatic Alzheimer’s disease (AD).
How to Identify and Tackle Treatment-Resistant Depression in Geriatric Patients Psychiatric Times, March 17, 2021
"The problem of treatment-resistant depression in later life TRD-LL is increasingly recognized but remains poorly characterized,” Randall Espinoza, MD, MPH, told the audience at the American Association of Geriatric Psychiatry Annual Meeting. According to Espinoza, estimates of its prevalence run from 6% up to 40% in geriatric patients with depression, depending on how treatment-resistant depression (TRD) is defined.
Mental wellbeing declined significantly during 2020, global report finds Healio, March 16, 2021
A report that outlined global mental health during 2020 found societal circumstance and behavior had an “enormous impact” on mental wellbeing. A study finds the percentage of respondents whose mental health wellbeing posed clinical risk in 2019 vs 2020, rose from 14% to 26%.
Novel Therapeutic Target for Depression Identified Medscape, March 09, 2021
An anti-seizure medication appears to reduce anhedonia in patients with depression via a novel mechanism that may offer a new therapeutic target for the disorder, new research suggests. "Our study was the first randomized placebo-controlled trial to show that a drug affecting this kind of ion channel in the brain can improve depression and anhedonia in patients," senior investigator James Murrough, MD, PhD, associate professor of psychiatry and neuroscience, Icahn School of Medicine at Mount Sinai, New York City, said in a press release.